Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors

Haemophilia

Volumn 20, Issue 3, 2014, Pages 369-375

  Tran, H T T ^a,b   Sorensen B ^c,d   Rea, C J ^d   Bjornsen S ^a   Ueland, T ^e   Pripp, A H ^f   Tjonnfjord G E ^a,b   Holme, P A ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c BAXTER HEALTHCARE CORPORATION   (United States)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF OSLO   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Activated prothrombin complex concentrates; Haemophilia; Inhibitors; Recombinant activated FVII; Tranexamic acid

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; D DIMER; FIBRINOGEN; RECOMBINANT ACTIVATED FACTOR VII; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; UNCLASSIFIED DRUG; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATES;

ADULT; ALLERGIC REACTION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEMOPHILIA A; HEMOSTASIS; HUMAN; MAXIMUM CLOT FIRMNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; THROMBOEMBOLISM; BLOOD; LONGITUDINAL STUDY; MALE; MIDDLE AGED; THROMBOELASTOGRAPHY; YOUNG ADULT;

ADULT; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CROSS-OVER STUDIES; HEMOPHILIA A; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBELASTOGRAPHY; TRANEXAMIC ACID; YOUNG ADULT;

EID: 84898914313     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12318     Document Type: Article

References (38)

1. Makris M, Hay CR, Gringeri A, D'Oiron R. How I treat inhibitors in haemophilia. Haemophilia 2012; 18(Suppl. 4): 48-53.
2. Caviglia H, Candela M, Galatro G, Neme D, Moretti N, Bianco RP. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature. Haemophilia 2011; 17: 910-9.
3. Negrier C, Lienhart A, Numerof R et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia 2013; 19: e143-50.
4. Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care centres using FEIBA(R) for surgeries in patients with inhibitors. Haemophilia 2011; 17: 28-34.
5. Rodriguez-Merchan EC, Jimenez-Yuste V, Gomez-Cardero P, Alvarez-Roman M, Martin-Salces M, Rodriguez d. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience. Haemophilia 2010; 16: 84-8.
6. Zulfikar B, Aydogan G, Salcioglu Z et al. Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey 41. Haemophilia 2012; 18: 383-91.
7. Astermark J, Santagostino E, Keith HW. Clinical issues in inhibitors. Haemophilia 2010; 16(Suppl. 5): 54-60.
8. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
9. Sorensen B, Dargaud Y, Kenet G et al. On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII 13. Haemophilia 2012; 18: 255-62.
10. Valentino LAFAU, Allen GF, Gill JCFAU et al. Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia 2013; 19: 151-66.
11. Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG. Discordant fibrin formation in hemophilia. J Thromb Haemost 2009; 7: 825-32.
12. Foley JH, Nesheim ME, Rivard GE, Brummel-Ziedins KE. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. Haemophilia 2012; 18: e316-22.
13. Kazemi SM, Mosaffa F, Eajazi A et al. The effect of tranexamic acid on reducing blood loss in cementless total hip arthroplasty under epidural anesthesia. Orthopedics 2010; 33: 17.
14. Levi M. Should antifibrinolytics be given in all patients with trauma? Curr Opin Anaesthesiol 2012; 25: 385-8.
15. Roberts I, Shakur H, Coats T et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 2013; 17: 1-79.
16. Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA(R)) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A-a two-centre experience. Haemophilia 2012; 18: 544-9.
17. Young G, Sorensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013; 121: 1944-50.
18. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145: 24-33.
19. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
20. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
21. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
22. Astermark J, Donfield SM, Dimichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
23. Oldenburg J, Goudemand J, Valentino L et al. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia 2010; 16: 866-77.
24. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
25. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
26. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.
27. Ingerslev J, Sorensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 2011; 155: 256-62.
28. Wolberg AS. Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia 2010; 16(Suppl. 3): 7-12.
29. Rea CJ, Foley JH, Ingerslev J, Sorensen B. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. J Thromb Haemost 2011; 9: 510-6.
30. Foley JH, Petersen KU, Rea CJ et al. Solulin increases clot stability in whole blood from humans and dogs with hemophilia. Blood 2012; 119: 3622-8.
31. Rea CJ, Foley JH, Sorensen B. Factor XIII in the treatment of hemophilia A. N Engl J Med 2012; 366: 281-3.
32. Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5: 2408-14.
33. Prescribing Information, Baxter International Product Specification. May 2012.
34. Shakur H, Roberts I, Bautista R et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
35. Schulman S, Loogna J, Wallensten R. Minimizing factor requirements for surgery without increased risk. Haemophilia 2004; 10(Suppl. 4): 35-40.
36. Wang Q, Liu J, Fan R et al. Tranexamic acid reduces postoperative blood loss of degenerative lumbar instability with stenosis in posterior approach lumbar surgery: a randomized controlled trial. Eur Spine J 2013; 22: 9: 2035-8.
37. Hoffman M, Monroe DM. Platelet binding and activity of recombinant factor VIIa. Thromb Res 2010; 125(Suppl. 1): S16-8.
38. Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012; 120: 891-9.